ReviewCurrent treatment options in gastroenterology2017
Role of Zinc in the Development/Progression of Alcoholic Liver Disease.
Review in Current treatment options in gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 65 citations in OpenAlex.
- Iron and Other Metal Ions in Human Health and Disease.MedComm · 2026Review
- Review
- Comparative Absorption and Bioavailability of Various Chemical Forms of Zinc in Humans: A Narrative Review.Nutrients · 2024Review
- Current Pharmacotherapy and Nutrition Therapy of Alcohol-Associated Liver Disease.Clinics in liver disease · 2024Review
- Xenotransplanted human organoids identify transepithelial zinc transport as a key mediator of intestinal adaptation.Nature communications · 2024Article
- Multiomics Analysis of PCB126's Effect on a Mouse Chronic-Binge Alcohol Feeding Model.Environmental health perspectives · 2024Article
- Role of zinc in health and disease.Clinical and experimental medicine · 2024Review
- Nutritional Support for Alcoholic Liver Disease.Nutrients · 2023Review
- Article
- Prospective clinical trials and novel therapies in the medical management of severe alcohol-associated hepatitis.Clinical liver disease · 2022Review
- The Importance of Behavioral and Native Factors on COVID-19 Infection and Severity: Insights from a Preliminary Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2022Article
- Alcohol-Associated Tissue Injury: Current Views on Pathophysiological Mechanisms.Annual review of physiology · 2022Review
- Zinc and its role in vitamin D function.Current research in physiology · 2022Review
- The role of vitamin and microelement supplementation in the treatment of ethanol-induced liver disease.Przeglad gastroenterologiczny · 2022Review
- Oxidative Stress-A Key Player in the Course of Alcohol-Related Liver Disease.Journal of clinical medicine · 2021Review
- Managing medicines in alcohol-associated liver disease: a practical review.Australian prescriber · 2021Review
- Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives.International journal of molecular sciences · 2021Review
- Article
- Oxidative stress in alcohol-related liver disease.World journal of hepatology · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
opinion statementMany variables, aside from the amount and duration of alcohol consumption, play a role in the development and progression of alcoholic liver disease (ALD). One critical factor that can be modified is diet/nutrition. We have made major recent advances in our understanding of the interactions of nutrition and ALD. In this article, we review advances made in zinc metabolism/therapy for ALD. There is major zinc dyshomeostasis with ALD which is mediated, in part, by poor intake and absorption, increased excretion, and altered zinc transporters, especially ZIP14. Zinc deficiency plays an etiologic role in multiple mechanisms of ALD, ranging from intestinal barrier dysfunction to hepatocyte apoptosis. Zinc supplementation is highly effective at correcting these ALD mechanisms and preventing/treating experimental ALD. There is no Food and Drug Administration (FDA) approved therapy for any stage of ALD. Because animal and human data suggest that zinc deficiency occurs early in the course of ALD, we treat most ALD patients with daily oral zinc supplementation (220 mg zinc sulfate which contains 50 mg elemental zinc).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.